Pressure BioSciences (OTCQB: PBIO), a leader in the
development and sale of broadly enabling, pressure-based technology and
products to the worldwide life-sciences and other industries, recently executed
a contract services agreement with a well-known biotherapeutics firm. An
article discussing the company reads, “Under the terms of the agreement, the
firm will utilize PBIO’s proprietary BaroFold(TM) technology platform to
enhance the process manufacturing of one of its candidate protein drugs (http://ibn.fm/aidN2). . . .
PBIO’s BaroFold technology platform offers a unique and cost-effective way to
address the complex and often-challenging process of manufacturing the
recombinant proteins that are required in the development of protein-based drugs.
Two of the major challenges associated with manufacturing recombinant proteins
are (1) the formation of aggregates and (2) protein misfolding. These are
significant issues that can prevent a protein drug candidate from ever making
it to market.”
To view the full article, visit http://ibn.fm/hlGIm
About Pressure BioSciences Inc.
Pressure BioSciences (OTCQB: PBIO) is a leader in the
development and sale of innovative, broadly enabling, pressure-based solutions
for the worldwide life-sciences industry. The company’s products are based on
the unique properties of both constant (i.e., static) and alternating (i.e.,
pressure cycling technology, or “PCT”) hydrostatic pressure. PCT is a
patented-enabling technology platform that uses alternating cycles of
hydrostatic pressure between ambient and ultra-high levels to safely and
reproducibly control biomolecular interactions (e.g., cell lysis, biomolecule
extraction). PBIO’s primary focus is in the development of PCT-based products
for biomarker and target discovery, drug design and development,
biotherapeutics characterization and quality control, soil and plant biology,
forensics and counter-bioterror applications. Additionally, major new market
opportunities have emerged in the use of the company’s pressure-based
technologies in the following areas: (1) the use of its recently acquired PreEMT
technology from BaroFold Inc. to allow entry into the biologics-contract,
research-services sector, and (2) the use of its recently patented, scalable,
high-efficiency, pressure-based Ultra Shear Technology (“UST”) platform to (i)
create stable nanoemulsions of otherwise immiscible fluids (e.g., oils and
water) and (ii) prepare higher-quality, homogenized, extended shelf-life or
room-temperature stable, low-acid liquid foods that cannot be effectively
preserved using existing nonthermal technologies. For more information, visit
the company’s website at www.PressureBiosciences.com.
NOTE TO INVESTORS: The latest news and updates
relating to PBIO are available in the company’s newsroom at http://ibn.fm/PBIO
About QualityStocksNewsBreaks
QualityStocksNewsBreaks provide
a rapid summary of corporate news that catch the attention of QualityStocks.
QualityStocksBreaks are designed to keep investors up to date on important and
breaking news in the small-cap and micro-cap markets. Spanning all industries,
including energy, entertainment, telecommunications, healthcare, retail and
more, these news breaks deliver opportunities the investment community may have
missed. Whether it is earnings results, mergers and acquisitions, or any other
market-moving news, our news breaks keep you in the know. QualityStocks is
committed to connecting subscribers with companies that have huge potential to
succeed in the short and long-term future. It is part of our mission statement
to help the investment community discover emerging companies that offer excellent
growth potential.
QualityStocks (QS)
Scottsdale, Arizona
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com
Scottsdale, Arizona
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com
Please see full terms of use and disclaimers on the
QualityStocks website applicable to all content provided by QS, wherever
published or re-republished: http://www.qualitystocks.net/disclaimer.php
No comments:
Post a Comment